Skip to main content
Erschienen in: Tumor Biology 6/2015

01.06.2015 | Research Article

Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma

verfasst von: ShanShan Yang, Ying Gao, Jing Sun, Bairong Xia, TianBo Liu, HongXia Zhang, Qi Li, Min Xiao, YunYan Zhang

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Concurrent chemoradiotherapy (cCRT) is the standard of care for International Federation of Gynecology and Obstetrics (FIGO) stage IIB squamous cervical carcinoma (SCC). However, an increasing number of young patients with stage IIB SCC are concerned with preserving their ovarian and vaginal functions during treatment. This retrospective study aimed to compare clinical prognosis between young patients with stage IIB SCC treated with neoadjuvant chemotherapy (NACT) followed by radical surgery (RS) and those treated with cCRT. Medical records of 244 premenopausal patients aged <45 years with FIGO stage IIB SCC treated with NACT+RS and cCRT between February 2007 and June 2009 were reviewed. All these patients completed the treatment plan. NACT+RS resulted in recurrence (35.9 versus 41.8 %, P = 0.350), progression-free survival (PFS) rate (log-rank, P = 0.456), and overall survival (OS) rate (log-rank, P = 0.637) comparable to cCRT. Compared with cCRT, NACT+RS did not show a significant statistical difference in clinical prognosis of premenopausal patients with stage IIB SCC. Therefore, NACT+RS may be considered as an alternative treatment for the young patients who are concerned with preserving endocrine function, and this alternative treatment may also be administered when radiotherapy is unavailable.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
4.
5.
Zurück zum Zitat Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.CrossRefPubMed Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.CrossRefPubMed
6.
7.
Zurück zum Zitat Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952–65.CrossRefPubMed Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952–65.CrossRefPubMed
8.
Zurück zum Zitat Suprasert P, Srisomboon J, Kasamatsu T. Radical hysterectomy for stage IIb cervical cancer: a review. Int J Gynecol Cancer. 2005;15:995–1001.CrossRefPubMed Suprasert P, Srisomboon J, Kasamatsu T. Radical hysterectomy for stage IIb cervical cancer: a review. Int J Gynecol Cancer. 2005;15:995–1001.CrossRefPubMed
9.
Zurück zum Zitat Undurraga M, Loubeyre P, Dubuisson JB, Schneider D, Petignat P. Early-stage cervical cancer: is surgery better than radiotherapy? Expert Rev Anticancer Ther. 2010;10:451–60.CrossRefPubMed Undurraga M, Loubeyre P, Dubuisson JB, Schneider D, Petignat P. Early-stage cervical cancer: is surgery better than radiotherapy? Expert Rev Anticancer Ther. 2010;10:451–60.CrossRefPubMed
10.
Zurück zum Zitat Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535–40.CrossRefPubMed Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535–40.CrossRefPubMed
11.
Zurück zum Zitat Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson M, et al. Cervical carcinoma: a drug-responsive tumor—experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecol Oncol. 1983;16:275–81.CrossRefPubMed Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson M, et al. Cervical carcinoma: a drug-responsive tumor—experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecol Oncol. 1983;16:275–81.CrossRefPubMed
12.
Zurück zum Zitat Lilic V, Lilic G, Filipovic S, Milosevic J, Tasic M, Stojiljkovic M. Modern treatment of invasive carcinoma of the uterine cervix. J Buon. 2009;14:587–92.PubMed Lilic V, Lilic G, Filipovic S, Milosevic J, Tasic M, Stojiljkovic M. Modern treatment of invasive carcinoma of the uterine cervix. J Buon. 2009;14:587–92.PubMed
13.
Zurück zum Zitat Legge F, Margariti PA, Lucidi A, Macchia G, Petrillo M, Iannone V, et al. Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: evaluation of toxicity and outcome measures. Acta Oncol. 2013;52:166–73.CrossRefPubMed Legge F, Margariti PA, Lucidi A, Macchia G, Petrillo M, Iannone V, et al. Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: evaluation of toxicity and outcome measures. Acta Oncol. 2013;52:166–73.CrossRefPubMed
14.
Zurück zum Zitat Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol. 2007;104:64–9.CrossRefPubMed Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol. 2007;104:64–9.CrossRefPubMed
15.
Zurück zum Zitat Benedetti Panici P, Bellati F, Pastore M, Manci N, Musella A, Pauselli S, et al. An update in neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 2007;107:S20–2.CrossRefPubMed Benedetti Panici P, Bellati F, Pastore M, Manci N, Musella A, Pauselli S, et al. An update in neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 2007;107:S20–2.CrossRefPubMed
16.
Zurück zum Zitat Sardi J, Sananes C, Giaroli A, Maya G, di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol. 1990;38:486–93.CrossRefPubMed Sardi J, Sananes C, Giaroli A, Maya G, di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol. 1990;38:486–93.CrossRefPubMed
17.
Zurück zum Zitat Angioli R, Plotti F, Luvero D, Aloisi A, Guzzo F, Capriglione S, et al. Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. Tumour Biol. 2014;35:2741–6.CrossRefPubMed Angioli R, Plotti F, Luvero D, Aloisi A, Guzzo F, Capriglione S, et al. Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. Tumour Biol. 2014;35:2741–6.CrossRefPubMed
18.
Zurück zum Zitat Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471–88.CrossRefPubMed Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471–88.CrossRefPubMed
19.
Zurück zum Zitat NCCN (National Comprehensive Cancer Network) clinical practice guidelines in Oncology:cervical cancer (2014.V1) NCCN (National Comprehensive Cancer Network) clinical practice guidelines in Oncology:cervical cancer (2014.V1)
20.
Zurück zum Zitat Shen K, Lang JH. Problems and challenges of gynecological oncology. Beijing: People’s Medical Publishing House; 2002. Shen K, Lang JH. Problems and challenges of gynecological oncology. Beijing: People’s Medical Publishing House; 2002.
21.
Zurück zum Zitat Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cardenas-Rebollo JM, et al. Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma International Federation of Gynecology and Obstetrics stage IB2-IIB. Int J Gynecol Cancer. 2013;23:1647–54.CrossRefPubMed Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cardenas-Rebollo JM, et al. Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma International Federation of Gynecology and Obstetrics stage IB2-IIB. Int J Gynecol Cancer. 2013;23:1647–54.CrossRefPubMed
22.
Zurück zum Zitat McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013;108:2464–9.CrossRefPubMedPubMedCentral McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013;108:2464–9.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Zhao EF, Bao L, Li C, Song L, Li YL. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:605–9.PubMed Zhao EF, Bao L, Li C, Song L, Li YL. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:605–9.PubMed
24.
Zurück zum Zitat Duenas-Gonzalez A, Cetina L, Mariscal I, de la Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003;29:389–99.CrossRefPubMed Duenas-Gonzalez A, Cetina L, Mariscal I, de la Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003;29:389–99.CrossRefPubMed
25.
Zurück zum Zitat Candelaria M, Chanona-Vilchis J, Cetina L, Flores-Estrada D, Lopez-Graniel C, Gonzalez-Enciso A, et al. Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. Int Semin Surg Oncol. 2006;3:3.CrossRefPubMedPubMedCentral Candelaria M, Chanona-Vilchis J, Cetina L, Flores-Estrada D, Lopez-Graniel C, Gonzalez-Enciso A, et al. Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. Int Semin Surg Oncol. 2006;3:3.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A, Mohar A, Rivera L, Mota A, et al. Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. Ann Oncol. 2002;13:1212–9.CrossRefPubMed Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A, Mohar A, Rivera L, Mota A, et al. Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. Ann Oncol. 2002;13:1212–9.CrossRefPubMed
27.
Zurück zum Zitat Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003;83 Suppl 1:41–78.CrossRefPubMed Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003;83 Suppl 1:41–78.CrossRefPubMed
28.
Zurück zum Zitat Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S. Radical hysterectomy for FIGO stage IIb cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol. 2009;114:69–74.CrossRefPubMed Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S. Radical hysterectomy for FIGO stage IIb cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol. 2009;114:69–74.CrossRefPubMed
29.
Zurück zum Zitat Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol. 2012;127:114–20.CrossRefPubMed Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol. 2012;127:114–20.CrossRefPubMed
30.
Zurück zum Zitat Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125:292–6.CrossRefPubMed Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125:292–6.CrossRefPubMed
31.
Zurück zum Zitat Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:420–7.CrossRefPubMed Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:420–7.CrossRefPubMed
32.
Zurück zum Zitat Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2012;124:92–7.CrossRefPubMed Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2012;124:92–7.CrossRefPubMed
33.
Zurück zum Zitat Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T, To N, et al. Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection—an analysis with mathematical statistics. Int J Gynecol Cancer. 1993;3:219–25.CrossRefPubMed Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T, To N, et al. Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection—an analysis with mathematical statistics. Int J Gynecol Cancer. 1993;3:219–25.CrossRefPubMed
34.
Zurück zum Zitat Wang H, Zhu L, Lu W, Xu H, Yu Y, Yang Y. Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer. World J Surg Oncol. 2013;11:301.CrossRefPubMedPubMedCentral Wang H, Zhu L, Lu W, Xu H, Yu Y, Yang Y. Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer. World J Surg Oncol. 2013;11:301.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007;107:310–5.CrossRefPubMed Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007;107:310–5.CrossRefPubMed
Metadaten
Titel
Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma
verfasst von
ShanShan Yang
Ying Gao
Jing Sun
Bairong Xia
TianBo Liu
HongXia Zhang
Qi Li
Min Xiao
YunYan Zhang
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3074-2

Weitere Artikel der Ausgabe 6/2015

Tumor Biology 6/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.